Kura Oncology, Inc. (KURA)

Kura Oncology received a $30 million milestone payment from Kyowa Kirin in October 2025, leading to a stock increase. The company presented preliminary data from its FTI programs at the ESMO Congress 2025. Kura Oncology released its earnings results on August 7th, reporting a loss of ($0.75) EPS, significantly missing the consensus estimate of $0.15. Insiders have sold shares worth $697,839 over the last six months. Weiss Ratings issued a "Sell (D-)" rating in October 2025, but Kura Oncology generally holds a consensus rating of "Moderate Buy". KURA stock was up 6.6% on October 27, 2025, and up 13.8% on October 28, 2025, but has decreased by 45.48% over the past year.

Demand seasonality does not directly apply to Kura Oncology's investigational drugs. Demand is driven by clinical trial progress, regulatory approvals, and the prevalence of specific cancer types. Revenue is influenced by collaboration agreements and milestone payments rather than direct product sales.

Kura Oncology is focused on developing small molecule product candidates targeting cancer signaling pathways, particularly in genetically defined cancer subsets. Ziftomenib, an inhibitor of the menin-KMT2A interaction, is in Phase 3 trials for acute leukemias. Tipifarnib, an FTI, is being investigated for HRAS mutant tumors and HNSCC. KO-2806 (Darlafarnib), a next-generation FTI, is being explored for solid tumors and in combination therapies. KO-947, an ERK inhibitor, is in Phase 1/2 development for MAPK pathway tumors.

Kura Oncology is headquartered in San Diego, California, United States. Its KOMET-017 Phase 3 trials for ziftomenib are global.

Kura Oncology's brand reputation has been positively influenced by the milestone payment for ziftomenib and promising data from FTI programs. Negative impacts include a significant miss on EPS and revenue expectations, a "Sell (D-)" rating from Weiss Ratings, and concerns about financial health indicated by an Altman Z-Score in the distress zone.

Kura Oncology has a mixed ownership structure. Institutional owners hold approximately 94.69% to 95.88% of the stock, with major holders including BlackRock, Inc. and Suvretta Capital Management, LLC. Insiders own approximately 1.83% to 6.40% of the stock.